{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Price TH"],"funding":["NCATS NIH HHS","NHLBI NIH HHS"],"pagination":["2153-61"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4626256"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["126(18)"],"pubmed_abstract":["High-dose granulocyte transfusion therapy has been available for 20 years, yet its clinical efficacy has never been conclusively demonstrated. We report here the results of RING (Resolving Infection in Neutropenia with Granulocytes), a multicenter randomized controlled trial designed to address this question. Eligible subjects were those with neutropenia (absolute neutrophil count <500/μL) and proven/probable/presumed infection. Subjects were randomized to receive either (1) standard antimicrobial therapy or (2) standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexamethasone. The primary end point was a composite of survival plus microbial response, at 42 days after randomization. Microbial respo"],"journal":["Blood"],"pubmed_title":["Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection."],"pmcid":["PMC4626256"],"funding_grant_id":["U01 HL072072","U01 HL072291","R01 HL072321","U01 HL072191","U01 HL072290","HL072305","UL1 TR000427","HL072072","HL072196","HL072283","U01 HL072305","HL072291","U01 HL072028","HL072290","HL072191","U01 HL072346","U01 HL072268","HL072268","HL072028","HL072346","HL072321","U01 HL072196","U01 HL072283"],"pubmed_authors":["McFarland J","Holter Chakrabarty J","Nichols WG","Sachais BS","Assmann SF","Williams E","Sloan SR","Boeckh M","Hamza TH","Ness PM","Parekh S","McCullough J","Friedman D","Strauss RG","Kiss JE","Price TH","Harrison RW","Cushing MM","King KE","Young JA"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection.","description":"High-dose granulocyte transfusion therapy has been available for 20 years, yet its clinical efficacy has never been conclusively demonstrated. We report here the results of RING (Resolving Infection in Neutropenia with Granulocytes), a multicenter randomized controlled trial designed to address this question. Eligible subjects were those with neutropenia (absolute neutrophil count <500/μL) and proven/probable/presumed infection. Subjects were randomized to receive either (1) standard antimicrobial therapy or (2) standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexamethasone. The primary end point was a composite of survival plus microbial response, at 42 days after randomization. Microbial respo","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Oct","modification":"2025-04-26T19:27:24.714Z","creation":"2019-03-27T02:01:02Z"},"accession":"S-EPMC4626256","cross_references":{"pubmed":["26333778"],"doi":["10.1182/blood-2015-05-645986"]}}